ClinicalTrials.gg
CompletedNCT05485818Updated Aug 3, 2022

Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction

A Phase 2 interventional study of Low Dose and Middle Dose in Acute Myocardial Infarction, sponsored by Beijing Northland Biotech. Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-03.

Sponsored by Beijing Northland Biotech. Co., Ltd. · Phase 2, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Myocardial Infarction with a site in China — 64 open to participants now, 73 under way, 8 of them phase 3. Myocardial Infarction · China.

Enrollment
94th of 107
62 · median 366
Started
2020
with 12 others
Phase 2
4 of 196
none open now
Registered
92nd of 196
by date

Among the 196 studies in Myocardial Infarction with a site in China, this one is the 94th largest by enrollment of the 107 interventional ones that give a count, is one of 13 that started in 2020, is one of 4 in phase 2, and was the 92nd registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

64 of the 196 studies in Myocardial Infarction with a site in China are open now. Recruiting first, the newest first:

59 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Myocardial Infarction with a site in China, or all of them as a file.
02

Study summary

A multicenter randomized double-blind placebo parallel control design was used in this study.60 subjects eligible for inclusion will be randomly assigned to either a low-dose (0.25ug/kg) medium-dose (0.5ug/kg) high-dose (2.0ug/kg) experimental drug group or a control group (placebo) at a ratio of 1:1:1:1.After randomization, subjects received the experimental drug or placebo once a day, intravenously, on day 2 to 7, 12 hours and 4 hours after PCI.Ninety days after PCI were observed.

Read the detailed description

Subjects underwent cardiovascular magnetic resonance imaging (CMR) on the 90th day after PCI, which was used to evaluate the myocardial salvage index myocardial infarction area, microvascular occlusion area, left ventricular ejection fraction (LVEF), left ventricular end-systolic volume (LVESV), and left ventricular end-diastolic volume (LVEDV).Echocardiography was performed on the 5th and the 90th day after PCI to evaluate the left indoor diameter (LV) and left atrial diameter (LA) of LVEF.

Physical examination routine blood coagulation function was performed on the 30th and 90th day after PCI in the screening period (pre-screening results were acceptable);Electrocardiogram (ECG) was performed on the 30th and the 90th day after PCI on the 2nd day after the first administration;During the screening period (results before screening are acceptable), vital signs should be measured from day 1 to day 7 after PCI (during each dose, vital signs should be measured twice on day 7, including before and after administration), on day 30 and day 90;Blood biochemical examinations were performed from day 2 to day 4, day 7, day 30, and day 90 after PCI before the first administration;Creatine kinase isoenzyme (CK-MB) hypersensitive troponin I(HS-CTNI) or troponin I(cTnI) and amino-terminal B-type natriuretic peptide precursor (NT-probNP) or B-type natriuretic peptide (BNP) were detected on day 2, day 3, day 4 and day 7 after PCI before the first administration.Tumor markers were detected and immunogenicity blood samples were collected 30 days after PCI before the first administration.Routine urinalysis was performed 90 days after PCI before the first administration;Adverse drug events and cardiovascular events were continuously recorded during the trial.

03

Conditions studied

  • Acute Myocardial Infarction

Keywords

  • AMI
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subject or its legal representative will voluntarily participate in the study and sign the ;
  2. Age 18 and 75, regardless of gender;
  3. STEMI patients with left anterior descending branch single-artery middle occlusion (TIMI grading 0\~1, see Appendix 1 for TIMI grading) and receiving PCI;
  4. No obvious collateral of coronary artery (Rentrop grade 0\~1,Rentrop grade see Appendix 2);
  5. Chest pain occurred for 6 hours and 12 hours before PCI;
  6. TIMI grade 3 after PCI;
  7. All subjects (male and female) must agree to use appropriate methods (hormonal or barrier contraceptive methods, abstinence) during the study period and up to 6 months after the last administration, and women of childbearing age must test negative for pregnancy before administration.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have a history of myocardial infarction or have received coronary artery acute thrombolytic interventional therapy with bypass surgery;
  2. patients who received thrombolytic therapy after onset;
  3. patients who were clearly diagnosed as acute heart failure (Killip grade II,Killip classification in annex 3);
  4. Severe arrhythmia that cannot be corrected;
  5. Aortic dissection or suspected presence;
  6. Severe liver and kidney dysfunction or severe depletion, etc;
  7. major surgical history or hemorrhagic stroke in half a year;
  8. Has or has a history of ;
  9. Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg in patients with hypertension after active antihypertensive treatment;
  10. Clinically, he had a significant history of allergy, especially to mannitol, drugs, protein preparations and biological products;
  11. Screening of patients who participated in other clinical studies within the first 3 months;
  12. Failure to perform CMR test: such as claustrophobia, renal failure ( \< 30ml/min);
  13. Other conditions not considered suitable for inclusion by the researcher.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
62 participants (actual)

Study arms

  • Experimental
    Low Dose

    Patients in this treatment group will receive NL005 for 0.25 ug/kg respective.Continuous administration for 7 days.

    Drug: Low Dose

  • Experimental
    Middle Dose

    Patients in this treatment group will receive NL005 for 0.5 ug/kg respective.Continuous administration for 7 days.

    Drug: Middle Dose

  • Experimental
    High Dose

    Patients in this treatment group will receive NL005 for 2.0 ug/kg respective.Continuous administration for 7 days.

    Drug: High Dose

  • Placebo comparator
    Placebo

    Patients in this treatment group will receive placebo respective. Continuous administration for 7 days.

    Other: Placebo

Interventions

  • DrugLow Dose

    12±4 hours after PCI: 0.25 ug/kg Recombinant Human Thymosin β4 (intravenous injection),Day2-Day7 after PCI:0.25 ug/kg Recombinant Human Thymosin β4 (intravenous injection)

    Also known as: NL005( Low Dose)

  • DrugMiddle Dose

    12±4 hours after PCI: 0.5 ug/kg Recombinant Human Thymosin β4 (intravenous injection),Day2-Day7 after PCI:0.5 ug/kg Recombinant Human Thymosin β4 (intravenous injection)

    Also known as: NL005( Middle Dose)

  • DrugHigh Dose

    12±4 hours after PCI: 2.0 ug/kg Recombinant Human Thymosin β4 (intravenous injection),Day2-Day7 after PCI:2.0 ug/kg Recombinant Human Thymosin β4 (intravenous injection)

    Also known as: NL005(High Dose)

  • OtherPlacebo

    15 subjects will be randomly assigned to the placebo for 7 days

06

What researchers measure

Primary outcomes

  1. Change of myocardial infarction area on Day 5 and day 90 after PCI

    Change of myocardial infarction area on Day 5 and day 90 after PCI. Myocardial infarction area day 5 and day 90 after PCI,and the change on day 90 compared to day 5. Myocardial infarction size was evaluated by late gadolinium enhanced cardiac magnetic resonance (LGE-CMR) imaging.

    Time frame: Day 5、Day 90

Secondary outcomes

  1. Change of myocardial salvage index on Day 5 and day 90 after PCI

    Myocardial salvage index day 5 and day 90 after PCI,and the change on day 90 compared to day 5. Myocardial salvage index (%) defifined as: (area at risk-infarct size)/ area at risk\*100% measured by CMR. Higher scores mean a better outcome.

    Time frame: Day 5、Day 90

  2. Change of microvascular obstruction area on Day 5 and day 90 after PCI

    Area of microvascular obstruction day 5 and day 90 after PCI,and the change on day 90 compared to day 5. Microvascular obstruction is one of the risk factors affecting the prognosis of AMI patients. The occurrence of MVO is related to the release of cytotoxic factors caused by distal microvascular embolization and reperfusion injury. Studies have shown a significantly increased risk of heart failure, adverse cardiovascular events, and death. late gadolinium enhancement (LGE) was performed to identify areas of microvascular obstruction (MVO), the typical MVO is the low signal area in the high signal area of infarction.

    Time frame: Day 5、Day 90

  3. Change of LA on Day 5 and day 90 after PCI

    Change of left atrium (LA) on Day 5 and day 90 after PCI, The data of LA after PCI were measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

    Time frame: Day 5、Day 90

  4. Changeof LV on Day 5 and day 90 after PCI

    Change of left ventricle (LV) on Day 5 and day 90 after PCI, Day 5 and day 90 LV after PCIwere measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

    Time frame: Day 5、Day 90

  5. Change of LVEF on Day 5 and day 90 after PCI

    Change of Left Ventricular Ejection Fractions (LVEF) on Day 5 and day 90 after PCI, Day 5 and day 90 LVEF after PCIwere measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

    Time frame: Day 5、Day 90

  6. Change of LVESV on Day 5 and day 90 after PCI

    Change of Left Ventricular end-systolic volume (LVESV) on Day 5 and day 90 after PCI, Day 5 and day 90 LVESV after PCI were measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

    Time frame: Day 5、Day 90

  7. Change of LVEDV on Day 5 and day 90 after PCI

    Change of Left Ventricular end-diastolic volume (LVEDV) on Day 5 and day 90 after PCI, Day 5 and day 90 LVEDV after PCI were measured by CMR at Day 5 and day 90, and calculate changes in data day 90 and day 5.

    Time frame: Day 5、Day 90

  8. Number of participants with treatment-related adverse events as assessed by NCI-CTCAE v5.0

    Number of participants with adverse events (AE), treatment-related adverse events, abnormal vital signs, abnormal physical examination findings, abnormal laboratory test results, abnormal electrocardiograms

    Time frame: Day0、Day1、Day2、Day3、Day4、Day5、Day6、Day7、Day30、Day90

  9. Incidence of anti-drug antibody (ADA)

    Blood samples were collected before administration and 30 days after PCI to evaluate the immunogenicity of NL005

    Time frame: Day 0、Day 30

07

Study locations

1 site
  • Fuwai Hospital, Chinese Academy of Medical Sciences
    Beijing, China
08

References and documents

Publications

  • Limana F, Capogrossi MC, Germani A. The epicardium in cardiac repair: from the stem cell view. Pharmacol Ther. 2011 Jan;129(1):82-96. doi: 10.1016/j.pharmthera.2010.09.002. Epub 2010 Oct 19. PubMed 20937304 ↗
  • Wrigley BJ, Lip GY, Shantsila E. The role of monocytes and inflammation in the pathophysiology of heart failure. Eur J Heart Fail. 2011 Nov;13(11):1161-71. doi: 10.1093/eurjhf/hfr122. Epub 2011 Sep 27. PubMed 21952932 ↗
  • Gutierrez SH, Kuri MR, del Castillo ER. Cardiac role of the transcription factor NF-kappaB. Cardiovasc Hematol Disord Drug Targets. 2008 Jun;8(2):153-60. doi: 10.2174/187152908784533702. PubMed 18537603 ↗
  • Gordon JW, Shaw JA, Kirshenbaum LA. Multiple facets of NF-kappaB in the heart: to be or not to NF-kappaB. Circ Res. 2011 Apr 29;108(9):1122-32. doi: 10.1161/CIRCRESAHA.110.226928. PubMed 21527742 ↗
  • Srivastava D, Ieda M, Fu J, Qian L. Cardiac repair with thymosin beta4 and cardiac reprogramming factors. Ann N Y Acad Sci. 2012 Oct;1270:66-72. doi: 10.1111/j.1749-6632.2012.06696.x. PubMed 23050819 ↗
  • Dube KN, Bollini S, Smart N, Riley PR. Thymosin beta4 protein therapy for cardiac repair. Curr Pharm Des. 2012;18(6):799-806. doi: 10.2174/138161212799277699. PubMed 22236126 ↗

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Sep 2021, 10 months.

Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 7, 2020
First posted
Aug 3, 2022
StartActual
Nov 23, 2020
Primary completionActual
Sep 30, 2021
CompletionActual
Nov 18, 2021
Last update
Aug 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05485818
Lead sponsor
Beijing Northland Biotech. Co., Ltd.
Responsible party
Sponsor
First posted
Aug 3, 2022
Start date
Nov 23, 2020
Primary completion
Sep 30, 2021
Completion
Nov 18, 2021
Last update
Aug 3, 2022

Study contacts

KeFei Dou
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion